Small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-01EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
European Medicines Agency authorises Hetronifly (serplulimab) for multiple indications including small cell lung cancer, non-small cell lung…
-
EMA approval · 2026-03-31EMA Authorised: Topotecan Hospira (topotecan) — Pfizer Europe MA EEIG
EMA authorised Topotecan Hospira for use in small cell lung cancer and uterine cervical neoplasms.
-
EMA approval · 2026-03-30EMA Authorised: Tecentriq (atezolizumab) — Roche Registration GmbH
The European Medicines Agency authorized Tecentriq (atezolizumab) by Roche Registration GmbH for multiple cancer indications, including non-…
-
EMA approval · 2026-03-27New treatment for relapsed extensive-stage small cell lung cancer
The European Medicines Agency announces Imdylltra as a new treatment for relapsed extensive-stage small cell lung cancer, addressing an unme…
-
FDA approval · 2026-02-27FDA Approved: ZEPZELCA — Supplemental Application (Jazz Pharmaceuticals, Inc.)
FDA approved a supplemental application for ZEPZELCA (lurbinectedin) filed by Jazz Pharmaceuticals, expanding the regulatory status of the p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-26EMA Authorised: Tevimbra (tislelizumab) — Beone Medicines Ireland Limited
EMA authorised Tevimbra (tislelizumab) from Beone Medicines Ireland Limited for multiple cancer indications, including esophageal squamous c…
-
EMA approval · 2026-01-20EMA Authorised: Hycamtin (topotecan) — Sandoz Pharmaceuticals d.d.
EMA authorised Hycamtin (topotecan) by Sandoz Pharmaceuticals d.d. for the treatment of ovarian cancer, cervical cancer, and small cell lung…
-
EMA approval · 2026-01-12EMA Authorised: Hetronifly (serplulimab) — Accord Healthcare S.L.U.
EMA authorised Hetronifly (serplulimab) for small cell lung cancer, with Accord Healthcare S.L.U. as the marketing authorisation holder. The…
-
FDA approval · 2025-10-02FDA Approved: ZEPZELCA — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ZEPZELCA (lurbinectedin) from Jazz Pharmaceuticals. This action pertains to the NDA for the …
-
FDA approval · 2025-08-25FDA Approved: COSELA — Supplemental Application (G1 Therapeutics, Inc.)
FDA approved a supplemental application for COSELA (trilaciclib) from G1 Therapeutics.
-
FDA approval · 2025-04-30FDA Approved: ZEPZELCA — Supplemental Application (Jazz Pharmaceuticals, Inc.)
FDA approved a supplemental application for Zepzelca (lurbinectedin) by Jazz Pharmaceuticals, Inc. The action approves changes to the drug's…
-
CLINICAL_TRIALS approval · 2025-03-10Clinical Trial Update: Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Amgen's tarlatamab (AMG 757) expanded access protocol for advanced small cell lung cancer has been approved for marketing.
-
EMA approval · 2025-01-20EMA Authorised: Potactasol (topotecan) — Actavis Group PTC ehf
The EMA has authorised Potactasol (topotecan) for cervical cancer and small cell lung cancer, with Actavis Group PTC ehf as the marketing au…
-
FDA approval · 2024-05-10FDA Approved: CISPLATIN — Original Application (Apotex Corp.)
FDA approved the original application for cisplatin from Apotex Corp., enabling the generic version to be marketed in the United States.
-
FDA approval · 2023-08-03FDA Approved: COSELA — Supplemental Application (G1 Therapeutics, Inc.)
FDA approved a supplemental application for COSELA (trilaciclib) by G1 Therapeutics, Inc., expanding its labeling to include its use as a my…
-
FDA approval · 2023-07-28FDA Approved: ZEPZELCA — Supplemental Application (Jazz Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ZEPZELCA (lurbinectedin) submitted by Jazz Pharmaceuticals, Inc.
-
FDA approval · 2023-06-16FDA Approved: CARBOPLATIN — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for generic carboplatin. This action permits Apotex to market a generic carboplatin for…
-
FDA approval · 2021-02-12FDA Approved: COSELA — Original Application (G1 Therapeutics, Inc.)
The FDA approved COSELA (trilaciclib) from G1 Therapeutics in an original NDA to preserve bone marrow function during chemotherapy in adults…
-
FDA approval · 2020-08-20FDA Approved: TOPOTECAN HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare's supplemental application for Topotecan Hydrochloride, a generic chemotherapy drug, supporting its labeling …
-
FDA approval · 2020-06-15FDA Approved: ZEPZELCA — Original Application (Jazz Pharmaceuticals, Inc.)
The FDA approved Zepzelca (lurbinectedin) from Jazz Pharmaceuticals in an original-application approval for adult patients with metastatic s…
-
FDA approval · 2020-03-05FDA Approved: CARBOPLATIN — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for carboplatin filed by Apotex Corp., authorizing changes to an approved generic product.
-
FDA approval · 2017-07-06FDA Approved: TOPOTECAN — Original Application (Accord Healthcare Inc.)
The FDA approved Accord Healthcare Inc.'s original application for a generic Topotecan. This approval makes a generic version of Topotecan a…
-
FDA approval · 2017-03-17FDA Approved: CISPLATIN — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' original application for cisplatin, a generic injectable chemotherapy agent (ANDA approval).
-
FDA approval · 2017-01-19FDA Approved: CISPLATIN — Supplemental Application (WG Critical Care, LLC)
The FDA approved a supplemental application for cisplatin submitted by WG Critical Care, LLC.
-
FDA approval · 2015-11-17FDA Approved: TOPOTECAN HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare's supplemental application for Topotecan hydrochloride, enabling a generic version of the cancer drug to be m…